Object. Brainstem dysfunction occurs in a minority of patients with myelomeningocele (MMC), most of whom have Chiari Type II malformation. Some surgeons advocate early identification of these patients for craniocervical decompression to avoid significant mortality. The auditory brainstem response has been found to be abnormal in most children with MMC. The present study examines whether failure of routine newborn hearing screening (NHS) predicts brainstem dysfunction in MMC patients.
©AANS, 2014
B rainstem dysfunction is the most common cause of death in newborns with myelomeningocele (MMC). 9 Most newborns with MMC have associated Chiari Type II malformation. Brainstem dysfunction occurs in 20% of patients with MMC 23 and is traditionally considered to arise from brainstem dysgenesis in Chiari Type II malformation and resultant mechanical stress on the brainstem and cranial nerves. 7, 24 However, similar symptoms have been reported in MMC in the absence of Chiari Type II malformation. 20 Surgical treatment of brainstem dysfunction in these patients is controversial. 2, 15, 23 Some surgeons advocate early craniocervical decompression in patients who become symptomatic, 23, 25, 26, 31 particularly because of the poor prognosis for children who develop bilateral vocal cord paralysis. 22, 34 Unfortunately, prediction of symptom development remains difficult.
Past researchers have investigated the utility of auditory function testing for predicting symptom development in children with MMC. Most patients with MMC have abnormal results on auditory brainstem response (ABR) testing, with prolonged interpeak latencies (IPLs) 1, 14, 33 reflecting slow peripheral 12, 18, 21 and central 5, 6, 18, 19, 21 auditory neurotransmission. Normalization of central auditory function over time, coupled with progressively worsening peripheral auditory function, suggests intrinsic brainstem improvement with simultaneous cranial nerve stretching. 18, 21 Some authors have had success correlating ABR results with symptoms, 14, 30, 33 though not in older children. 5 Case reports describe ABR improvement after craniocervical decompression. 10, 29 Automated ABR testing is commonly used in the universal newborn hearing screening (NHS) programs that were introduced throughout the United States in the midto late 1990s. 28 These programs were designed to identify hearing loss early by screening newborns before hospital discharge. Most studies of auditory impairment in MMC were published before the advent of universal NHS, and no prior research has examined whether NHS failure predicts development of brainstem dysfunction in these patients.
In the present study, we examined the records of patients born with MMC and identified those who failed NHS. We hypothesized that newborns with MMC would fail NHS more often than newborns without MMC who also stayed in the neonatal intensive care unit (NICU) after birth. We further hypothesized that among patients with MMC, newborns who failed NHS would be more likely to develop symptoms of brainstem dysfunction than would newborns who passed.
Methods

Study Design and Population
This study was approved by the University of Minnesota Institutional Review Board. Using the Data Access Service operated by the University of Minnesota Informatics Consulting Service, we identified the medical rec ords of newborns with and without MMC. All patients included in this study were born between 2003 and 2014, stayed in the NICU for at least 1 day immediately after birth, and had medical encounters recorded in the Fairview Health Services electronic medical record (EMR) system. All eligible patients born with MMC during the study period were included. For the control group, 50 eligible patients were randomly selected.
We excluded patients with a significant risk of hearing loss: those with cranial malformations, syndromes associated with hearing loss, or both. We also excluded patients with very low birth weight (< 1500 g), which is a known risk factor for hearing loss. 4 Finally, we excluded newborns with hydrocephalus from the control group, since hydrocephalus may contribute to auditory dysfunction in patients with MMC.
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Data Collection
Data were retrospectively obtained from the EMR and stored securely in the Academic Health Center Information Exchange Data Shelter. Birth demographics recorded included sex, birth weight, gestational age at birth, and age at NICU discharge. Audiological data comprised age at NHS, screening modality, NHS result, and-in the case of NHS failure-audiological follow-up. Surgical history encompassed age at MMC repair, shunt placement, and craniocervical decompression, if applicable. The length of medical followup was defined as the age at the most recent in-person medical encounter recoded in the EMR.
To identify presence and age of onset for symptoms of brainstem dysfunction, we reviewed neurosurgical encounters and examined the EMR for symptom term occurrences via text search, individually verifying search results. Symptoms were grouped into 5 categories and identified using search terms as follows (exact search term in parentheses). Respiratory symptoms included apnea (apne-), stridor (stridor), and vocal cord dysfunction (vocal cord). Swallowing dysfunction was defined as dysphagia (dysphagia), diminished gag reflex (gag reflex), or swallowing difficulties (swallow). Facial nerve palsy was reported as weakness of the facial nerve (facial) or cranial nerve VII (VII). Upper-extremity weakness was identified as poor arm strength (strength) or arm weakness (weak). Opisthotonus (opis-) comprised its own category.
Statistical Analysis
All statistical analyses were performed with SAS version 9.3 (SAS Institute Inc.). Continuous data were compared with the Mann-Whitney U-test. Categorical data were compared with Fisher's exact test. A 2-tailed p value < 0.05 was considered statistically significant.
Results
Demographics
Forty patients with MMC and 50 patients without MMC met the eligibility criteria for this study. Of the newborns with MMC, 85% (34/40) had associated Chiari Type II malformation, and 15% (6/40) had MMC alone. Demographics for the MMC and NICU control groups are given in Table 1 . Sex did not vary between patients with MMC (19 male and 21 female) and those without MMC (29 male and 21 female; p = 0.40). Birth weight was marginally greater in patients with MMC (median 3050 g) than in those without MMC (median 2858 g; p = 0.085). Gestational age was significantly greater in patients with MMC (median 38 weeks) than in those without MMC (median 37 weeks; p = 0.012). Age at NHS and NICU discharge did not vary between patients with MMC (median 10 days and 12 days, respectively) and those without MMC (median 3 days and 8 days, respectively; p = 0.15), although a minority of patient records included the screening date. The most common screening modality was ABR (35 MMC patients and 38 control patients), though in several cases the modality was not reported.
Results of NHS for MMC Patients and NICU Controls
Of newborns with both MMC and Chiari Type II malformation, 15% (5/34) failed NHS; none with MMC alone failed NHS. Overall, patients with MMC failed NHS (13%, 5/40) more often than did control patients (0%, 0/50; p = 0.015; Table 2 ). Patients with MMC who developed brainstem symptoms failed NHS (31%, 4/13) more often than did controls (p = 0.001), whereas patients with MMC who never developed brainstem symptoms did not (4%, 1/27; p = 0.35).
Surgical Procedures and Follow-Up in Patients With MMC
Among patients born with MMC, surgical history was similar between newborns who passed NHS and those who failed (Table 3 ). All patients underwent MMC repair, and the age at repair did not differ between patients who failed and those who passed NHS (median 1 day for both groups; p = 0.73), although 1 patient who passed NHS underwent in utero MMC repair. All patients with hydrocephalus underwent shunt placement. The 5 newborns who failed NHS all received shunts (median 5 days), while 71% (25/35) of newborns who passed NHS underwent shunt placement (median 14 days; p = 0.31 for shunting, p = 0.18 for age at shunting). One patient (20%, 1/5) who failed NHS underwent craniocervical decompression for Chiari Type II malformation at 6 months of age, and 3 patients (9%, 3/35) who passed NHS underwent decompression (median 18 months; p = 0.43 for decompression, p = 0.66 for age at decompression). Medical follow-up did not vary between MMC patients who failed NHS (median 32 months) and those who passed (median 26 months; p = 0.86).
Symptoms of Brainstem Dysfunction
Respiratory dysfunction and swallowing dysfunction were the only brainstem symptoms identified; no patient was reported to demonstrate facial nerve weakness, upper-extremity weakness, or opisthotonus (Table 3 ). All MMC patients who developed brainstem symptoms had respiratory dysfunction, which was more common and occurred later in MMC patients who failed NHS (80%, 4/5; median 16 months) than in those who passed (26%, 9/35; median 0 months; p = 0.031 for symptom presence, p = 0.022 for symptom onset). Swallowing dysfunction did not vary in prevalence or onset between patients who failed NHS (40%, 2/5; median 3 months) and those who passed (9%, 3/35; median 1 month; p = 0.11 for symptom presence, p = 0.81 for symptom onset). Overall, symptom presence was more common in patients who failed NHS (80%, 4/5) than in those who passed (26%, 9/35; p = 0.031), but the onset of the first symptom did not quite vary significantly (median 3 and 0 months for NHS failure and passage, respectively; p = 0.064).
Test metrics were calculated for NHS as a predictor of brainstem symptom development. The sensitivity and specificity were 0.31 (4/13) and 0.96 (26/27), respectively, and the positive and negative predictive values were 0.80 (4/5) and 0.74 (26/35), respectively. Table 4 summarizes data for the 13 patients with MMC who developed brainstem symptoms, including 4 of the 5 patients who failed NHS. Of the newborns who failed NHS, 3 had unilateral failure and 2 had bilateral failure. Unfortunately, little audiological follow-up information was found in these patients' records. Three patients (Patients 1, 3, and 4 in Table 4 ) had no follow-up data in the medical record. One patient (Patient 2 in Table  4 ) was found on follow-up to have bilateral conductive hearing loss and underwent bilateral pressure equalization tube placement at 10 months of age; ABR testing immediately after pressure equalization tube insertion demonstrated mild hearing loss, worse in the ear that originally failed NHS. The patient who failed NHS but never showed brainstem symptoms had normal audiological test results at 5 months of age.
Audiological Follow-Up
Discussion
Several authors have contended that early recognition of brainstem dysfunction in patients with MMC and Chiari Type II malformation is critical for both prognostic evaluation 9, 22 and surgical candidate identification.
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This argument is based primarily on the high mortality rate and poor surgical outcomes of patients with vocal cord paralysis. 9, 22, 34 However, identification of newborns who will go on to develop brainstem dysfunction continues to be challenging.
Diagnostic ABR Testing in Patients With MMC
Many studies have investigated ABR testing for early detection of brainstem dysfunction in patients with MMC. 1, 5, 6, 12, 14, 18, 19, 21, 33 Waves I, III, and V of the ABR are believed to originate from the distal auditory nerve, cochlear nucleus, and lateral lemniscus, respectively. 17 The IPL between Waves I and V (I-V IPL), which reflects conduction time from inner ear to midbrain, is prolonged in most patients with MMC. 1, 5, 6, 12, 14, 33 The III-V IPL is initially prolonged 5, 19 but normalizes with age, 6,18,21 suggesting delayed brainstem maturation in MMC. In contrast, the I-III IPL increases with age, consistent with growing tension on the auditory nerve. 18, 21 Some researchers have demonstrated ABR variation between MMC patients with brainstem dysfunction and those without. Lütschg et al. 14 found that the I-V IPL was longest in patients with stridor. Worley et al. 33 reported that the I-V IPL was significantly longer in newborns who developed brainstem symptoms than in those who did not. Taylor et al. 30 found ABR abnormalities more frequently in patients with brainstem dysfunction and noted low amplitude of Waves III-V in abnormal ABR results. Further evidence for the ABR as a test for brainstem dysfunction comes from reports of ABR improvement and clinical recovery after craniocervical decompression.
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Newborn Hearing Screening in Patients With MMC
Universal NHS was established to improve early identification and management of hearing loss. In Minnesota, before hospital discharge newborns undergo NHS using ABR or otoacoustic emissions (OAE) testing; infants who fail NHS should undergo audiological followup examination by 3 months of age. 16 The sensitivity of NHS has been reported to be 49% for mild hearing impairment and 89% for bilateral hearing loss. 32 Prior research has found abnormal audiological findings in 38% of patients who failed NHS in the well-baby nursery. 13 The positive predictive value depends on pretest probability, so newborns with MMC may be less likely to have false-positive NHS results.
Automated ABR testing in NHS offers multiple logistic benefits over diagnostic ABR testing for predicting future brainstem dysfunction. First, automated ABR testing has a binary outcome, making interpretation simple. In contrast with diagnostic ABR testing, automated ABR testing assesses not IPLs but, rather, the presence of Wave V after a click of 35 dB above normal hearing level. The absence of Wave V constitutes NHS failure. Second, because automated ABR testing measures successful auditory neurotransmission rather than latency times, there is no need to compare latency times with normal values, which vary with time because of normal progressive myelination of the brainstem. 11 Third, automated ABR testing must be performed in the newborn period before hospital discharge, avoiding misleading results for patients tested at older ages. 5 In the present study, we found that patients with MMC who developed symptoms of brainstem dysfunction failed NHS more often (31%, 4 of 13 patients) than did patients without MMC who likewise stayed in the NICU after birth (0%, 0 of 50 patients). The magnitude of this difference is underscored by the overall rarity of NHS failure, reported to be 3% and 1% for newborns in the NICU and well-baby nursery, respectively. 3, 13 In comparison, patients with MMC who remained asymptomatic rarely failed NHS (4%, 1 of 27 patients). Given the high prevalence of ABR IPL abnormalities in patients with MMC but without brainstem symptoms, 6 NHS appears to be more specific than diagnostic ABR testing as a marker for brainstem dysfunction.
As we hypothesized, patients with MMC who failed NHS were more likely to develop symptoms of brainstem dysfunction than were patients with MMC who passed NHS. However, the relative frequency of craniocervical decompression did not vary between these 2 groups of patients, perhaps because of low statistical power or conservative surgical management. The patient who failed NHS and underwent decompression required repeat decompression 5 months later, suggesting severe brainstem dysfunction.
Interestingly, we observed variation in age at symptom onset by NHS result. Respiratory dysfunction, which was present in all symptomatic cases, occurred later in patients who failed NHS. Three of 4 patients (75%) who failed NHS had respiratory dysfunction after 1 year of age, compared with only 1 of 9 patients (11%) who passed NHS. It is mechanistically unclear why newborns failing NHS would be more likely to develop respiratory dysfunction at an older age. Nonetheless, this phenomenon may be clinically useful because it is more important to identify at-risk newborns than newborns who have already been diagnosed with brainstem dysfunction.
We found NHS to be a low-sensitivity (0.31) but highspecificity (0.96) test for development of brainstem dysfunction. The positive (0.80) and negative (0.74) predictive values were reasonable for clinical use. Taken together, these data suggest that NHS is a useful adjunct to longitudinal symptom monitoring in determining prognosis and need for surgical intervention in patients with MMC.
Limitations
Several limitations of the present study merit discussion. Patients with syndromes associated with hearing loss were excluded because those syndromes provided independent explanation of abnormal NHS results. However, such causes of hearing loss may not be diagnosed early, and caution should be exercised in the possibility of nonbrainstem related auditory dysfunction. The newborns with MMC had longer gestation and marginally greater birth weight than did their NICU counterparts without MMC. These disparities could have led to underestimation of differences in NHS results between the 2 groups, since shorter gestation and smaller birth weight are associated with NHS failure, 4, 27 but no NICU control patients failed NHS. The screening modality was not reported for several newborns in this study, and at least 2 patients-neither of whom failed NHS or showed symptoms of brainstem dysfunction-underwent testing of OAE rather than ABR. Otoacoustic emissions reflect cochlear function 8 and may be normal despite impairment of the auditory pathway; therefore, ABR testing is preferable for assessment of brainstem dysfunction in patients with MMC.
Identification of symptoms from health care provider notes in the EMR may have under-or overestimated the prevalence of true symptoms of brainstem dysfunction in patients with MMC. It was challenging to ascertain whether a given symptom occurrence was related to brainstem dysfunction. Therefore, we included all symptoms (e.g., sporadic, unexplained apneic episodes) that were not attributed to another source. This methodology may account in part for the 9 of 13 symptomatic patients who did not undergo craniocervical decompression. Additionally, intermittent symptoms of brainstem dysfunction may have gone unnoticed by the neurosurgical team or may have been less severe than continuous symptoms, thereby contributing to the low frequency of decompression among symptomatic patients.
The size and retrospective design of this study also limit interpretation of the data. Our sample of patients with MMC was small, and our conclusions are based on the 5 patients who failed NHS. Though medical follow-up time did not vary by NHS result, in some cases neurosurgical or audiological care was sought outside the hospital network covered by our EMR system. This was made particularly evident by the lack of audiological follow-up data for patients who failed NHS. Although patient volume and follow-up are ever-present issues, a larger, prospective study could help to overcome some of these limitations.
Conclusions
This retrospective study provides evidence for the utility of NHS for the prediction of brainstem dysfunction development in newborns with MMC. We found that newborns with MMC and symptoms of brainstem dysfunction failed NHS more frequently than newborns without MMC. We observed that patients with MMC who failed NHS were more likely to develop brainstem symptoms than were those who passed, and that respiratory symptom onset occurred later in patients failing NHS. We conclude that NHS may be a useful tool for early identification of newborns with MMC who are at risk for brainstem dysfunction. Results of NHS may be considered during prognostic and surgical evaluation of these patients to reduce mortality from respiratory failure and other complications of brainstem dysfunction.
